Background.<\/strong> Long COVID, also termed post-COVID-19 condition or post-acute sequelae of SARS-CoV-2 infection (PASC), is a heterogeneous multisystem disorder that may follow mild or severe acute infection. Increasing evidence implicates persistent immune dysregulation and, in defined patient subsets, autoimmunity. The central question is no longer whether SARS-CoV-2 can induce persistent immune abnormalities, but rather which immune abnormalities are pathogenic, in which patients, and through which molecular and physiologic pathways.<\/p>\n\n\n\n Methods.<\/strong> We reviewed clinical, immunologic, neurologic, genomic, transcriptomic, proteomic, and mechanistic studies addressing autoimmunity and long COVID, emphasizing randomized studies, longitudinal cohorts, genome-wide association studies, mechanistic experiments, and investigations published through August 2026.<\/p>\n\n\n\n Results.<\/strong> Long COVID is associated with persistent alterations in innate and adaptive immunity, including abnormal T-cell differentiation, exhausted or dysfunctional SARS-CoV-2-specific CD8+ T cells, altered B-cell responses, complement activation, chronic inflammatory signaling, and persistent metabolic abnormalities. Autoantibodies directed against diverse cellular antigens occur in subsets of patients. Particularly compelling recent evidence links antibodies directed against central and peripheral nervous-system proteins with neurological long COVID and provides experimental evidence that patient-derived immunoglobulin can induce neurologic abnormalities in animals. Autoantibodies directed against G-protein\u2013coupled receptors and other autonomic or vasoregulatory targets may contribute to dysautonomia in another subset. Blood\u2013brain-barrier disruption, endothelial dysfunction, altered tissue perfusion, viral persistence, and reactivation of latent viruses may amplify or perpetuate autoimmune injury. Host genetics appear to modify susceptibility; a large genome-wide association study identified a reproducible association between long COVID and the FOXP4<\/em> locus, while HLA variation and other immune-related loci remain plausible determinants of antigen presentation and immune persistence.<\/p>\n\n\n\n Conclusions.<\/strong> The emerging model of long COVID is not one of a single autoimmune disease but of several overlapping postviral immunopathologic syndromes. SARS-CoV-2 may initiate persistent disease through combinations of antigen persistence, aberrant immune activation, molecular mimicry, defective immune regulation, vascular injury, autonomic dysfunction, and genetically determined differences in antigen presentation. Definitive proof of pathogenic autoimmunity requires demonstration that a specific autoantibody or autoreactive lymphocyte population is necessary and sufficient to produce a clinical phenotype and that targeted immunomodulation improves that phenotype. The immediate research priority is therefore biomarker-defined, mechanistically stratified clinical trials rather than indiscriminate immunosuppression.<\/p>\n\n\n\n The emergence of persistent symptoms following SARS-CoV-2 infection has established long COVID as one of the most consequential postinfectious disorders of the modern era. The syndrome encompasses fatigue, post-exertional malaise, cognitive dysfunction, autonomic disturbances, dyspnea, chest pain, sensory abnormalities, sleep disturbance, gastrointestinal symptoms, headache, and a variety of neurological and systemic manifestations. Its clinical heterogeneity has complicated both epidemiologic measurement and mechanistic investigation.<\/p>\n\n\n\n The accumulating evidence, however, increasingly argues against a purely nonspecific model of postviral convalescence. Multiple independent investigations have demonstrated persistent alterations in immune-cell populations, inflammatory signaling, complement, antibody responses, and cellular metabolism months after the acute infection has resolved.\u00b9\u2013\u2076<\/p>\n\n\n\n Among these observations, autoimmunity has acquired particular importance. SARS-CoV-2 infection is capable of inducing broad autoreactive antibody responses during acute disease, and persistent autoantibodies have been detected in subsets of patients with long COVID.\u2077\u2013\u2079 More recently, investigators have identified autoantibodies against neural proteins in patients with neurological long COVID and have provided experimental evidence suggesting that at least some of these antibodies may be functionally pathogenic rather than merely epiphenomenal.\u00b9\u2070\u2013\u00b9\u00b2<\/p>\n\n\n\n The distinction is crucial. An antibody detected after infection is not necessarily an autoimmune antibody in the pathogenic sense. True autoimmune pathogenesis requires evidence that the immune response is directed against self-antigens, persists in association with disease, perturbs cellular physiology, and contributes causally to tissue dysfunction. The field is only beginning to satisfy these criteria.<\/p>\n\n\n\n The most defensible contemporary model therefore regards autoimmunity as one component of a multifactorial post-SARS-CoV-2 pathophysiologic network<\/strong>, potentially dominant in particular phenotypes.<\/p>\n\n\n\n SARS-CoV-2 initiates disease through infection of epithelial and other susceptible cells, followed by innate immune activation, interferon signaling, complement activation, inflammatory cytokine production, and development of virus-specific adaptive immunity. In most individuals, this response eventually resolves the infection and returns the immune system toward homeostasis.<\/p>\n\n\n\n In susceptible individuals, however, several events may prevent restoration of immunologic equilibrium.<\/p>\n\n\n\n First, viral antigen may persist in anatomical compartments after respiratory infection has apparently resolved. Viral RNA or protein has been reported in gastrointestinal, pulmonary, lymphoid, vascular, neurologic, and other tissues.\u00b9\u00b3 Persistent antigen does not necessarily mean persistent infectious virus; nevertheless, continued antigenic stimulation provides a biologically plausible mechanism for maintaining immune activation.<\/p>\n\n\n\n Second, SARS-CoV-2 can produce profound perturbation of immune-cell populations. Longitudinal studies have identified persistent differences in T-cell subsets, increased inflammatory signaling, altered cytotoxic lymphocyte activity, and abnormalities of SARS-CoV-2-specific cellular and humoral responses.\u00b3\u2013\u2075<\/p>\n\n\n\n Third, acute infection can generate autoreactive antibodies. SARS-CoV-2 has a particularly strong capacity to stimulate broad B-cell activation, potentially through tissue injury, epitope spreading, molecular mimicry, and dysregulated germinal-center responses.\u2077,\u2078<\/p>\n\n\n\n Fourth, infection can disrupt vascular and epithelial barriers. Endothelial injury, altered coagulation, impaired microvascular regulation, and blood\u2013brain-barrier dysfunction may expose normally sequestered antigens and permit immune mediators to reach tissues that are ordinarily protected.\u00b9\u2074,\u00b9\u2075<\/p>\n\n\n\n These processes need not be mutually exclusive. Persistent antigen can stimulate immunity; inflammation can damage tissue; tissue damage can expose self-antigens; autoreactive B and T cells can amplify injury; and vascular-barrier dysfunction can facilitate immune access to additional tissues.<\/p>\n\n\n\n The resulting disease may therefore become self-sustaining after the initiating viral event has substantially diminished<\/strong>.<\/p>\n\n\n\n The autoimmune hypothesis rests upon several observations.<\/p>\n\n\n\n Large-scale protein-array studies have demonstrated extensive autoreactivity in long COVID. Patients with neurological and neurocognitive manifestations may have antibodies directed against proteins expressed within the central and peripheral nervous systems.\u2077,\u00b9\u2070<\/p>\n\n\n\n The breadth of these responses is notable. Rather than resembling a single classical autoimmune disease, long COVID appears capable of generating a heterogeneous autoreactive repertoire.<\/p>\n\n\n\n The presence of particular autoantibodies has been associated with specific clinical manifestations.<\/p>\n\n\n\n Antibodies directed against vasoregulatory and autonomic receptors have been associated with neurological and dysautonomic manifestations.\u00b9\u2076,\u00b9\u2077 Studies published in 2026 have strengthened the association between GPCR-directed antibodies and long-COVID physiology, although their pathogenicity remains under investigation.\u00b9\u2078,\u00b9\u2079<\/p>\n\n\n\n This phenotype\u2013antibody relationship is important because it suggests that long COVID may contain immunologically defined subgroups<\/strong>, rather than representing a single uniform disease.<\/p>\n\n\n\n The strongest evidence for autoimmunity does not come from antibody detection but from functional experiments.<\/p>\n\n\n\n A 2026 study reported that individuals with neurocognitive symptoms had increased autoantibodies directed against central and peripheral nervous-system proteins.\u00b9\u2070 Experimental work subsequently demonstrated that immunoglobulin derived from patients with neurological long COVID could induce sensory abnormalities after transfer into mice.\u00b9\u00b9<\/p>\n\n\n\n The findings do not establish that these antibodies explain cognitive dysfunction in all patients. They nevertheless move the field beyond simple association toward experimental evidence of biological activity.<\/p>\n\n\n\n Longitudinal studies have demonstrated immune abnormalities extending many months beyond acute infection.\u00b3\u2013\u2075 A 2025 investigation found persistent activation of inflammatory, complement, metabolic, and immune-exhaustion pathways for more than 180 days.\u00b2\u2070<\/p>\n\n\n\n Persistence is essential to an autoimmune hypothesis: transient autoreactivity during acute infection is common in severe viral disease and need not constitute chronic autoimmunity.<\/p>\n\n\n\n Several mechanisms could generate autoimmunity after SARS-CoV-2 infection.<\/p>\n\n\n\n Molecular mimicry occurs when microbial antigens resemble host proteins sufficiently to activate lymphocytes that subsequently recognize self.<\/p>\n\n\n\n SARS-CoV-2 contains numerous peptides with potential structural or sequence relationships to human proteins. Whether specific instances of molecular mimicry account for clinically important long COVID remains unresolved.<\/p>\n\n\n\n A rigorous demonstration would require:<\/p>\n\n\n\n The current literature has not established this sequence for the majority of long-COVID phenotypes.<\/p>\n\n\n\n Tissue injury can expose previously concealed antigens and create new targets for adaptive immunity.<\/p>\n\n\n\n SARS-CoV-2 infection produces extensive epithelial, endothelial, pulmonary, neurologic, and systemic inflammation. Damaged cells release intracellular proteins that may subsequently become immunogenic.<\/p>\n\n\n\n This mechanism could help explain why autoreactivity may broaden over time.<\/p>\n\n\n\n Long COVID is characterized in some cohorts by abnormal B-cell differentiation and altered antibody responses.\u2074,\u2075<\/p>\n\n\n\n A normal antiviral response requires controlled expansion followed by contraction of activated B-cell populations. Failure of this process can produce persistent plasmablast activity, abnormal antibody repertoires, and increased autoreactivity.<\/p>\n\n\n\n The resulting antibodies may be:<\/p>\n\n\n\n The distinction is clinically important because conventional measures of total immunoglobulin concentration cannot capture this complexity.<\/p>\n\n\n\n Neurological disease may represent one of the clearest examples of immune-mediated long COVID.<\/p>\n\n\n\n The blood\u2013brain barrier (BBB) normally restricts passage of antibodies, cytokines, immune cells, and circulating toxins into the central nervous system.<\/p>\n\n\n\n Studies using dynamic contrast-enhanced magnetic resonance imaging have demonstrated BBB disruption in patients with long-COVID cognitive impairment.\u00b9\u2075<\/p>\n\n\n\n This provides a potential mechanistic bridge:<\/p>\n\n\n\n SARS-CoV-2 infection \u2192 endothelial injury \u2192 BBB disruption \u2192 increased exposure of neural tissue to circulating immune mediators and antibodies \u2192 neuroinflammation and altered neuronal function.<\/strong><\/p>\n\n\n\n The BBB may therefore function not merely as a passive barrier but as a critical component of long-COVID pathophysiology.<\/p>\n\n\n\n A 2026 study provided evidence that patients with neurological long COVID can harbor autoantibodies against central and peripheral nervous-system proteins.\u00b9\u2070<\/p>\n\n\n\n The targets identified across studies include proteins involved in:<\/p>\n\n\n\n The emerging evidence suggests that neurological long COVID may therefore include a spectrum of autoimmune neuropathophysiology<\/strong>, ranging from subtle receptor dysfunction to more conventional antibody-mediated neurological syndromes.<\/p>\n\n\n\n This may be particularly relevant to patients with:<\/p>\n\n\n\n The autonomic nervous system regulates cardiovascular tone, gastrointestinal motility, thermoregulation, sweating, bladder function, and numerous visceral processes.<\/p>\n\n\n\n Long COVID frequently produces autonomic manifestations resembling POTS, inappropriate sinus tachycardia, orthostatic intolerance, and other dysautonomias.<\/p>\n\n\n\n GPCRs are central to autonomic physiology. \u03b2-adrenergic and muscarinic receptors, among others, regulate cardiovascular and autonomic signaling.<\/p>\n\n\n\n Autoantibodies against these receptors have therefore attracted considerable attention. Recent studies have reported associations between GPCR-directed antibodies and long-COVID dysautonomia.\u00b9\u2076\u2013\u00b9\u2079<\/p>\n\n\n\n The conceptual model is:<\/p>\n\n\n\n autoreactive IgG \u2192 receptor agonism or antagonism \u2192 abnormal autonomic signaling \u2192 altered vascular tone and heart-rate regulation \u2192 orthostatic intolerance and exertional symptoms.<\/strong><\/p>\n\n\n\n This hypothesis is biologically attractive, but the field must avoid a critical error: correlation between antibody concentration and symptoms does not prove receptor-mediated causality<\/strong>.<\/p>\n\n\n\n Functional assays and randomized antibody-targeted interventions are required.<\/p>\n\n\n\n The vascular endothelium occupies a pivotal position between immune and metabolic physiology.<\/p>\n\n\n\n SARS-CoV-2 can injure endothelial cells directly or indirectly through inflammatory signaling. Persistent endothelial dysfunction may result in:<\/p>\n\n\n\n A 2026 mechanistic model has proposed endothelial cellular senescence as a potential bridge linking persistent inflammation, vascular dysfunction, oxidative stress, impaired tissue repair, and chronic immune activation.\u00b2\u00b9<\/p>\n\n\n\n This model is provocative but remains a hypothesis rather than established clinical doctrine.<\/p>\n\n\n\n The physiological consequence could nevertheless be substantial.<\/p>\n\n\n\n A muscle or brain region may receive adequate blood flow at rest but fail to appropriately augment perfusion during increased demand. This could contribute to exertional intolerance, cognitive dysfunction, and post-exertional symptom exacerbation.<\/p>\n\n\n\n The immune system and cellular metabolism are tightly coupled.<\/p>\n\n\n\n Persistent inflammatory signaling alters:<\/p>\n\n\n\n Long COVID studies have demonstrated abnormalities in metabolic pathways and mitochondrial-associated processes.\u00b2,\u00b2\u00b2<\/p>\n\n\n\n An autoimmune process could aggravate these abnormalities in several ways.<\/p>\n\n\n\n Inflammatory cytokines can inhibit mitochondrial function; endothelial dysfunction can reduce oxygen delivery; autonomic abnormalities can impair metabolic regulation; and antibodies directed against cellular proteins could interfere directly with receptor or enzymatic function.<\/p>\n\n\n\n The result may be a functional energetic deficit<\/strong> in which conventional resting measurements appear relatively normal while physiologic reserve is markedly impaired.<\/p>\n\n\n\n This model has particular relevance to post-exertional malaise.<\/p>\n\n\n\n The existence of persistent immune disease after infection raises an obvious question:<\/p>\n\n\n\n Why do some individuals recover completely whereas others develop chronic disease?<\/strong><\/p>\n\n\n\n The answer almost certainly includes host genetics.<\/p>\n\n\n\n The strongest current genome-wide evidence comes from the Long COVID Host Genetics Initiative.<\/p>\n\n\n\n In a 2025 Nature Genetics<\/em> study involving up to 6,450 long-COVID cases and more than one million population controls, investigators identified a genome-wide significant association involving the FOXP4<\/em> locus. The association was replicated in independent cohorts.\u00b2\u00b3<\/p>\n\n\n\n The lead variant was associated with an increased risk of long COVID, and FOXP4<\/em> is biologically relevant to pulmonary epithelial biology and lung physiology. The investigators estimated long-COVID heritability across analyses at approximately 1% to 12%, depending on the phenotype and case\u2013control definition.\u00b2\u00b3<\/p>\n\n\n\n These findings establish an important principle:<\/p>\n\n\n\n Long COVID has a measurable host-genetic component, but it is not a simple Mendelian disorder.<\/strong><\/p>\n<\/blockquote>\n\n\n\n The effect of any individual variant is modest.<\/p>\n\n\n\n HLA molecules determine which peptides are presented to T cells.<\/p>\n\n\n\n Variation in HLA genes can therefore influence:<\/p>\n\n\n\n HLA variation has already been associated with susceptibility and severity of acute COVID-19.\u00b2\u2074<\/p>\n\n\n\n Whether particular HLA alleles determine susceptibility to autoimmune long COVID remains an important unresolved question.<\/p>\n\n\n\n A plausible model is:<\/p>\n\n\n\n HLA genotype \u2192 peptide presentation \u2192 quality of antiviral response \u2192 probability of antigen persistence or autoreactivity \u2192 phenotype of long COVID.<\/strong><\/p>\n\n\n\n This would explain why two individuals experiencing apparently similar SARS-CoV-2 infections can have radically different clinical trajectories.<\/p>\n\n\n\n Single-cell and multi-omic studies increasingly reveal that long COVID is accompanied by durable changes in gene expression.<\/p>\n\n\n\n One 2026 study identified a distinctive circulating monocyte transcriptional state characterized by TGF-\u03b2 and WNT\u2013\u03b2-catenin signaling and associated with fatigue severity.\u00b2\u2075<\/p>\n\n\n\n These findings are important because they demonstrate that persistent disease is not simply a subjective clinical phenomenon.<\/p>\n\n\n\n The immune system itself retains a measurable molecular memory of the infection.<\/p>\n\n\n\n This altered state includes:<\/p>\n\n\n\n The precise direction of causality remains uncertain.<\/p>\n\n\n\n Persistent viral antigen could drive the immune state; alternatively, an autoimmune process could maintain it after antigen has disappeared.<\/p>\n\n\n\n Most likely, both processes occur in different patients<\/strong>.<\/p>\n\n\n\n The apparent opposition between “viral persistence” and “autoimmunity” is probably artificial.<\/p>\n\n\n\n Persistent antigen could continually stimulate B and T cells.<\/p>\n\n\n\n The sequence might be:<\/p>\n\n\n\n viral persistence \u2192 chronic antigen presentation \u2192 persistent lymphocyte activation \u2192 autoreactive clone expansion \u2192 autoantibody production \u2192 tissue injury.<\/strong><\/p>\n\n\n\n Alternatively:<\/p>\n\n\n\n acute SARS-CoV-2 infection \u2192 autoreactivity \u2192 tissue injury \u2192 release of additional antigens \u2192 epitope spreading \u2192 chronic autoimmunity.<\/strong><\/p>\n\n\n\n A third possibility is:<\/p>\n\n\n\n viral persistence + autoimmunity + endothelial dysfunction<\/strong>, each reinforcing the others.<\/p>\n\n\n\n This integrated model is more consistent with the heterogeneity observed clinically.<\/p>\n\n\n\n SARS-CoV-2 infection can perturb immune surveillance sufficiently to permit reactivation of latent viruses, particularly herpesviruses.<\/p>\n\n\n\n Epstein\u2013Barr virus has attracted particular attention because EBV reactivation has been associated with fatigue and other long-COVID phenotypes.\u00b2\u2076<\/p>\n\n\n\n The significance of EBV is still debated.<\/p>\n\n\n\n It is possible that EBV reactivation is:<\/p>\n\n\n\n The distinction requires intervention studies.<\/p>\n\n\n\n Nevertheless, viral reactivation provides another route by which an initially self-limited SARS-CoV-2 infection could evolve into chronic immune stimulation.<\/p>\n\n\n\n The clinical manifestations of autoimmune long COVID can be understood as consequences of several interacting physiologic systems.<\/p>\n\n\n\n Autoantibodies, neuroinflammation, BBB dysfunction, impaired cerebral perfusion, and autonomic abnormalities may contribute to:<\/p>\n\n\n\n Autonomic receptor dysfunction and endothelial abnormalities may produce:<\/p>\n\n\n\n Persistent epithelial injury, endothelial dysfunction, immune activation, and altered lung physiology may contribute to dyspnea and impaired exertional reserve.<\/p>\n\n\n\n The association between long COVID and FOXP4<\/em> is particularly noteworthy because of the gene’s relationship to pulmonary biology.\u00b2\u00b3<\/p>\n\n\n\n The gastrointestinal tract may represent both an immunologic organ and a potential site of persistent viral antigen.<\/p>\n\n\n\n Alterations in intestinal permeability, microbiota, mucosal immunity, and autonomic regulation may interact to produce nausea, abdominal discomfort, altered bowel function, and dysmotility.<\/p>\n\n\n\n Mitochondrial dysfunction, impaired perfusion, autonomic dysregulation, inflammatory signaling, and altered skeletal-muscle metabolism may converge to produce profound exercise intolerance.<\/p>\n\n\n\n Long COVID generally begins during or after apparent recovery from acute SARS-CoV-2 infection.<\/p>\n\n\n\n The clinical trajectory can be divided conceptually into four phases.<\/p>\n\n\n\n The initial infection produces viral replication and innate and adaptive immune activation.<\/p>\n\n\n\n The severity of acute disease influences risk but does not determine it. Long COVID can follow mild, outpatient infection.<\/p>\n\n\n\n Symptoms may fail to resolve or may recur after an apparent recovery.<\/p>\n\n\n\n This phase may include:<\/p>\n\n\n\n Some patients develop a relatively stable syndrome.<\/p>\n\n\n\n Others experience fluctuating symptoms, often with marked worsening following physical or cognitive exertion.<\/p>\n\n\n\n This variability is compatible with disorders involving autonomic regulation, immune signaling, metabolic reserve, and vascular physiology.<\/p>\n\n\n\n Patients follow divergent trajectories.<\/p>\n\n\n\n Some experience substantial spontaneous improvement.<\/p>\n\n\n\n Others develop chronic disease lasting years.<\/p>\n\n\n\n A third group experiences relapsing-remitting disease.<\/p>\n\n\n\n This heterogeneity is one of the strongest arguments against a single pathological mechanism.<\/p>\n\n\n\n The autoimmune model is powerful precisely because it is unlikely to be universal.<\/p>\n\n\n\n Three broad phenotypes may eventually emerge.<\/p>\n\n\n\n Characteristics may include:<\/p>\n\n\n\n These patients might benefit from targeted immunomodulation.<\/p>\n\n\n\n Patients may have:<\/p>\n\n\n\n Antiviral strategies could be more rational for this group.<\/p>\n\n\n\n Patients may demonstrate:<\/p>\n\n\n\n Such patients may require different therapeutic strategies.<\/p>\n\n\n\n Most patients probably occupy overlapping categories.<\/p>\n\n\n\n The autoimmune hypothesis naturally raises the possibility of immunotherapy.<\/p>\n\n\n\n But this must be approached cautiously.<\/p>\n\n\n\n Corticosteroids, B-cell depletion, intravenous immunoglobulin, plasma exchange, JAK inhibition, and other immunomodulatory therapies can have serious adverse effects.<\/p>\n\n\n\n The critical question is not:<\/p>\n\n\n\n “Does long COVID involve the immune system?”<\/p>\n<\/blockquote>\n\n\n\n It clearly does.<\/p>\n\n\n\n The question is:<\/p>\n\n\n\n “Which immune abnormality is pathogenic in a particular patient, and can correcting it improve disease?”<\/strong><\/p>\n<\/blockquote>\n\n\n\n This distinction should determine future clinical trials.<\/p>\n\n\n\n A patient with demonstrable pathogenic neural autoantibodies should not necessarily receive the same treatment as a patient with evidence of viral persistence.<\/p>\n\n\n\n Similarly, an individual with autonomic receptor antibodies may require a different intervention from one whose principal abnormality is post-exertional metabolic dysfunction.<\/p>\n\n\n\n The future of long-COVID medicine will probably depend upon biomarkers capable of assigning patients to mechanistic subgroups.<\/p>\n\n\n\n Potential classes include:<\/p>\n\n\n\n Autoantibody panels<\/strong><\/p>\n\n\n\n Cellular immune signatures<\/strong><\/p>\n\n\n\n Molecular signatures<\/strong><\/p>\n\n\n\n Viral measurements<\/strong><\/p>\n\n\n\n Physiologic measures<\/strong><\/p>\n\n\n\n The objective should be a multidimensional biological classification<\/strong>, not a single universal long-COVID blood test.<\/p>\n\n\n\n Several fundamental questions remain unresolved.<\/p>\n\n\n\n The temporal relationship between infection, autoreactivity, and symptoms remains incompletely defined.<\/p>\n\n\n\n This is the most important question.<\/p>\n\n\n\n The recent neural-antibody experiments are encouraging because they provide functional evidence, but they do not yet establish that these antibodies account for the majority of neurological long COVID.\u00b9\u2070,\u00b9\u00b9<\/p>\n\n\n\n Potential explanations include:<\/p>\n\n\n\n Sex differences in immune regulation are well established, but the precise relationship to long COVID remains unresolved.<\/p>\n\n\n\n Understanding recovery may be as important as understanding disease.<\/p>\n\n\n\n Patients who recover may successfully eliminate residual antigen, restore immune tolerance, normalize endothelial function, or suppress autoreactive clones.<\/p>\n\n\n\n Those processes could provide therapeutic targets.<\/p>\n\n\n\n The most coherent current model can be represented as follows:<\/p>\n\n\n\n SARS-CoV-2 infection<\/strong><\/p>\n\n\n\n \u2193<\/p>\n\n\n\n viral replication and tissue injury<\/strong><\/p>\n\n\n\n \u2193<\/p>\n\n\n\n innate immune activation<\/strong><\/p>\n\n\n\n \u2193<\/p>\n\n\n\n interferon, cytokine and complement signaling<\/strong><\/p>\n\n\n\n \u2193<\/p>\n\n\n\n adaptive immune activation<\/strong><\/p>\n\n\n\n \u2193<\/p>\n\n\n\n possible persistence of viral antigen<\/strong><\/p>\n\n\n\n \u2193<\/p>\n\n\n\n abnormal B- and T-cell regulation<\/strong><\/p>\n\n\n\n \u2193<\/p>\n\n\n\n autoreactive lymphocyte expansion<\/strong><\/p>\n\n\n\n \u2193<\/p>\n\n\n\n autoantibodies against neural, autonomic, endothelial or other tissue antigens<\/strong><\/p>\n\n\n\n \u2193<\/p>\n\n\n\n vascular and blood\u2013brain-barrier dysfunction<\/strong><\/p>\n\n\n\n \u2193<\/p>\n\n\n\n neuroinflammation + autonomic dysfunction + impaired tissue perfusion<\/strong><\/p>\n\n\n\n \u2193<\/p>\n\n\n\n metabolic\/mitochondrial dysfunction<\/strong><\/p>\n\n\n\n \u2193<\/p>\n\n\n\n persistent multisystem symptoms<\/strong><\/p>\n\n\n\n with viral reactivation, microbiome disruption, endothelial senescence and genetic susceptibility<\/strong> acting as amplifiers or modifiers.<\/p>\n\n\n\n This model does not require every patient to possess every abnormality.<\/p>\n\n\n\n Indeed, the clinical heterogeneity of long COVID strongly suggests that they do not.<\/p>\n\n\n\n The scientific understanding of long COVID has undergone a fundamental transition.<\/p>\n\n\n\n The early view of PASC as residual damage after an acute respiratory infection has become inadequate. The accumulating evidence instead supports a complex postviral disease in which persistent antigen, immune dysregulation, autoimmunity, vascular dysfunction, autonomic abnormalities, metabolic impairment, and host genetic susceptibility interact.<\/p>\n\n\n\n Autoimmunity is emerging as one of the most consequential components of this model.<\/p>\n\n\n\n The evidence is strongest for subgroups<\/strong> of patients, particularly those with neurological and autonomic manifestations. Autoantibodies directed against neural proteins have now been associated with neurological phenotypes, and experimental studies provide initial evidence that patient-derived immunoglobulins can exert biologic effects in vivo.\u00b9\u2070,\u00b9\u00b9 Autonomic receptor antibodies represent another potentially important phenotype.\u00b9\u2076\u2013\u00b9\u2079<\/p>\n\n\n\n The genetic evidence is equally important. The identification of a reproducible FOXP4<\/em> association demonstrates that host genotype influences susceptibility to long COVID and implicates pulmonary biology in disease risk.\u00b2\u00b3 More broadly, variation in antigen presentation, immune regulation, and tissue repair is likely to determine whether SARS-CoV-2 infection terminates in complete recovery or evolves into persistent disease.<\/p>\n\n\n\n Nevertheless, the field must resist premature reductionism. An autoantibody is not necessarily a pathogenic autoantibody; an inflammatory biomarker is not necessarily a disease driver; and persistence of viral RNA is not synonymous with persistent infectious virus.<\/strong><\/p>\n\n\n\n The decisive era of long-COVID research will therefore be defined not by the discovery of additional associations but by causal experiments<\/strong>.<\/p>\n\n\n\n The essential sequence is:<\/p>\n\n\n\n identify the biological abnormality \u2192 demonstrate its functional effect \u2192 define the phenotype in which it occurs \u2192 intervene selectively \u2192 demonstrate clinical reversal.<\/strong><\/p>\n\n\n\n If this strategy succeeds, long COVID will cease to be regarded as a single enigmatic syndrome and will instead become a collection of biologically defined postinfectious disorders for which mechanism-specific therapy can be developed.<\/p>\n\n\n\n That transition\u2014from syndromic medicine to molecularly stratified medicine\u2014is likely to constitute the most important advance in long-COVID research during the coming decade.<\/p>\n\n\n\n Abstract Background. Long COVID, also termed post-COVID-19 condition or post-acute sequelae of SARS-CoV-2 infection (PASC), is a heterogeneous multisystem disorder that may follow mild or severe acute infection. Increasing evidence […]<\/p>\n","protected":false},"author":2,"featured_media":15794,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[982,1260,836,1320,289,421,964],"tags":[],"class_list":["post-15760","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-b-cell","category-cd8-t-cell","category-immune-system","category-long-cov","category-long-haul-disease","category-pasc","category-t-cell"],"_links":{"self":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/15760","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15760"}],"version-history":[{"count":3,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/15760\/revisions"}],"predecessor-version":[{"id":15793,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/15760\/revisions\/15793"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/media\/15794"}],"wp:attachment":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15760"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15760"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15760"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\n\n\n\nIntroduction<\/h5>\n\n\n\n
\n\n\n\nI. Etiology: From Viral Infection to Persistent Immune Disease<\/h5>\n\n\n\n
Initiation by SARS-CoV-2<\/h5>\n\n\n\n
\n\n\n\nII. Autoimmunity as a Central Mechanistic Hypothesis<\/h5>\n\n\n\n
1. Autoantibodies occur after SARS-CoV-2 infection<\/h5>\n\n\n\n
2. Autoantibodies correlate with phenotype<\/h5>\n\n\n\n
3. Some antibodies demonstrate functional activity<\/h5>\n\n\n\n
4. Immune abnormalities persist after viral clearance<\/h3>\n\n\n\n
\n\n\n\nIII. Molecular Mechanisms of SARS-CoV-2\u2013Associated Autoimmunity<\/h5>\n\n\n\n
Molecular mimicry<\/h5>\n\n\n\n
\n
\n\n\n\nEpitope spreading<\/h5>\n\n\n\n
\n\n\n\nB-cell dysregulation<\/h5>\n\n\n\n
\n
\n\n\n\nIV. Neurological Autoimmunity<\/h5>\n\n\n\n
Blood\u2013brain-barrier dysfunction<\/h5>\n\n\n\n
\n\n\n\nNeural autoantibodies<\/h5>\n\n\n\n
\n
\n
\n\n\n\nV. Autonomic Autoimmunity<\/h5>\n\n\n\n
\n\n\n\nVI. Endothelium, Microcirculation, and Autoimmune Physiology<\/h5>\n\n\n\n
\n
\n\n\n\nVII. Mitochondrial and Metabolic Consequences<\/h5>\n\n\n\n
\n
\n\n\n\nVIII. Genomics and Susceptibility<\/h5>\n\n\n\n
\n
\n\n\n\nHLA and antigen presentation<\/h5>\n\n\n\n
\n
\n\n\n\nIX. Transcriptomics and the Persistent Immune State<\/h5>\n\n\n\n
\n
\n\n\n\nX. Viral Persistence and Autoimmunity: Competing or Complementary Hypotheses?<\/h5>\n\n\n\n
\n\n\n\nXI. Viral Reactivation as an Amplifier<\/h5>\n\n\n\n
\n
\n\n\n\nXII. Clinical Physiology<\/h5>\n\n\n\n
Neurologic<\/h5>\n\n\n\n
\n
Cardiovascular<\/h5>\n\n\n\n
\n
Pulmonary<\/h5>\n\n\n\n
Gastrointestinal<\/h5>\n\n\n\n
Musculoskeletal and metabolic<\/h3>\n\n\n\n
\n\n\n\nXIII. Clinical Course<\/h5>\n\n\n\n
Phase 1: Acute infection<\/h5>\n\n\n\n
Phase 2: Early postinfectious transition<\/h5>\n\n\n\n
\n
Phase 3: Persistent multisystem disease<\/h5>\n\n\n\n
Phase 4: Recovery, persistence, or relapse<\/h5>\n\n\n\n
\n\n\n\nXIV. Why Autoimmunity May Explain Some Patients but Not Others<\/h5>\n\n\n\n
Autoimmune-dominant disease<\/h5>\n\n\n\n
\n
Persistence-dominant disease<\/h5>\n\n\n\n
\n
Metabolic\/vascular-dominant disease<\/h5>\n\n\n\n
\n
\n\n\n\nXV. Therapeutic Implications<\/h5>\n\n\n\n
\n
\n
\n\n\n\nXVI. Biomarker Development<\/h5>\n\n\n\n
\n
\n
\n
\n
\n
\n\n\n\nXVII. Outstanding Questions<\/h5>\n\n\n\n
Is autoimmunity initiating or perpetuating disease?<\/h5>\n\n\n\n
Are autoantibodies pathogenic?<\/h5>\n\n\n\n
Why does autoimmunity persist?<\/h5>\n\n\n\n
\n
Why are women disproportionately affected by many postviral autoimmune syndromes?<\/h5>\n\n\n\n
Why do some patients recover?<\/h5>\n\n\n\n
\n\n\n\nXVIII. A Unified Pathophysiologic Model<\/h5>\n\n\n\n
\n\n\n\nConclusion<\/h5>\n\n\n\n
\n\n\n\nNumbered References<\/h5>\n\n\n\n
\n